Drug Overview
Merck & Co’s V114 is a 15-valent pneumococcal capsular polysaccharide conjugate vaccine, which is currently in Phase III development in the US and EU. V114 contains the 13 serotypes included in Prevnar 13 (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F, and 19A), as well as two additional serotypes (22F and 33F). Merck & Co is testing both an aluminum-adjuvanted and non-adjuvanted version of the vaccine.
Analyst Outlook
V114’s (15-valent pneumococcal conjugate vaccine; Merck & Co) broader serotype coverage gives it significant market potential, should it demonstrate broader immunogenicity to Prevnar 13 (13-valent pneumococcal conjugate vaccine; Pfizer) in Phase III studies.
If serotype shift occurs, V114 could replace Prevnar 13 on the market for adults aged 50 years and older due to its broader coverage and greater diversity in serotypes.
Merck & Co’s V114 is a 15-valent pneumococcal capsular polysaccharide conjugate vaccine, which is currently in Phase III development in the US and EU. V114 contains the 13 serotypes included in Prevnar 13 (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F, and 19A), as well as two additional serotypes (22F and 33F). Merck & Co is testing both an aluminum-adjuvanted and non-adjuvanted version of the vaccine.
Analyst Outlook
V114’s (15-valent pneumococcal conjugate vaccine; Merck & Co) broader serotype coverage gives it significant market potential, should it demonstrate broader immunogenicity to Prevnar 13 (13-valent pneumococcal conjugate vaccine; Pfizer) in Phase III studies.
If serotype shift occurs, V114 could replace Prevnar 13 on the market for adults aged 50 years and older due to its broader coverage and greater diversity in serotypes.
Table of Contents
OVERVIEW
LIST OF FIGURES
LIST OF TABLES
